Eui-Kyung Lee

List of Publications by Year
in descending order

68 papers	675 citations	623188 14 h-index	713013 21 g-index
68 all docs	68 docs citations	68 times ranked	1303 citing authors

#	Article	IF	Citations
1	Magnetic Resonance Imaging Is Cost‐Effective for Hepatocellular Carcinoma Surveillance in High‐Risk Patients With Cirrhosis. Hepatology, 2019, 69, 1599-1613.	3.6	70
2	Risk factors of asthma exacerbation based on asthma severity: a nationwide population-based observational study in South Korea. BMJ Open, 2018, 8, e020825.	0.8	48
3	Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B. Gut, 2021, 70, 2172-2182.	6.1	30
4	Food away from home and body mass outcomes: Taking heterogeneity into account enhances quality of results. Nutrition, 2014, 30, 1015-1021.	1.1	25
5	Health Care Utilization and Direct Costs in Mild, Moderate, and Severe Adult Asthma: A Descriptive Study Using the 2014 South Korean Health Insurance Database. Clinical Therapeutics, 2017, 39, 527-536.	1.1	24
6	Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea. Clinical Therapeutics, 2019, 41, 1066-1079.	1.1	23
7	Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea. Clinical Therapeutics, 2015, 37, 1662-1676.e2.	1.1	20
8	Easy cuts, easy rebound: Drug expenditures with massive price cuts in Korea. Health Policy, 2019, 123, 388-392.	1.4	19
9	Evaluation of the pilot program on the real-time drug utilization review system in South Korea. International Journal of Medical Informatics, 2013, 82, 987-995.	1.6	18
10	Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data. Rheumatology International, 2016, 36, 505-513.	1.5	18
11	Risk of neuropsychiatric adverse events associated with the use of oseltamivir: a nationwide population-based case-crossover study. Journal of Antimicrobial Chemotherapy, 2019, 74, 453-461.	1.3	18
12	The utility score of epilepsy with partial seizure measured by TTO, VAS, and EQ-5D in the general Korean population. Epilepsy Research, 2014, 108, 963-971.	0.8	16
13	Effects of computerized physician order entry on medication turnaround time and orders requiring pharmacist intervention. Research in Social and Administrative Pharmacy, 2014, 10, 756-767.	1.5	15
14	The effect of the introduction of a nationwide DUR system where local DUR systems are operating—The Korean experience. International Journal of Medical Informatics, 2015, 84, 912-919.	1.6	15
15	Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 411-419.	0.7	15
16	Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance Database. Seminars in Arthritis and Rheumatism, 2018, 47, 485-491.	1.6	14
17	Higher prevalence of dementia in patients with schizophrenia: A nationwide population‐based study. Asia-Pacific Psychiatry, 2016, 8, 145-153.	1.2	13
18	Beyond uncertainty: Negative findings for the association between the use of proton pump inhibitors and risk of dementia. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 2135-2143.	1.4	13

#	Article	IF	Citations
19	Economic Burden of Hypoglycemia in Patients with Type 2 Diabetes Mellitus from Korea. PLoS ONE, 2016, 11, e0151282.	1.1	12
20	Factors influencing the difference between forecasted and actual drug sales volumes under the price–volume agreement in South Korea. Health Policy, 2016, 120, 867-874.	1.4	12
21	Signal detection of benzodiazepine use and risk of dementia: sequence symmetry analysis using South Korean national healthcare database. International Journal of Clinical Pharmacy, 2018, 40, 1568-1576.	1.0	12
22	Cost–benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis. Clinical Therapeutics, 2015, 37, 2019-2027.	1.1	11
23	Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea. Clinical Therapeutics, 2016, 38, 2430-2446.e3.	1.1	11
24	National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007–2016 in South Korea. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 401-409.	0.7	11
25	Cost-Effectiveness of Tiotropium in Elderly Patients with Severe Asthma Using Real-World Data. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1939-1947.e7.	2.0	11
26	Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real–world evidence using a nationwide database. International Journal of Rheumatic Diseases, 2018, 21, 1227-1236.	0.9	10
27	Assessment of the Price–Volume Agreement Program in South Korea. Health Policy, 2016, 120, 1209-1215.	1.4	9
28	Healthcare Costs for Acute Hospitalized and Chronic Heart Failure in South Korea: A Multi-Center Retrospective Cohort Study. Yonsei Medical Journal, 2017, 58, 944.	0.9	9
29	Differences in the risk of mood disorders in patients with asthma-COPD overlap and in patients with COPD alone: a nationwide population-based retrospective cohort study in Korea. Respiratory Research, 2019, 20, 80.	1.4	9
30	Prevalence and predictors of hypoglycemia in South Korea. American Journal of Managed Care, 2018, 24, 278-286.	0.8	9
31	Comparison of benefit&ndash;risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experiments. Patient Preference and Adherence, 2016, 10, 641.	0.8	8
32	Effect of sex and age on the association between suicidal behaviour and obesity in Korean adults: a cross-sectional nationwide study. BMJ Open, 2016, 6, e010183.	0.8	8
33	Development of a transformation model to derive general population–based utility: Mapping the pruritus–visual analog scale (VAS) to the EQ–5D utility. Journal of Evaluation in Clinical Practice, 2017, 23, 755-761.	0.9	8
34	Use pattern and predictors of use of highly caffeinated energy drinks among South Korean adolescents: a study using the Health Belief Model. BMJ Open, 2017, 7, e017224.	0.8	8
35	The Utility of 5 Hypothetical Health States in Heart Failure Using Time Trade-Off (TTO) and EQ-5D-5L in Korea. Clinical Drug Investigation, 2018, 38, 727-736.	1.1	7
36	A Comparison of Leukotriene Receptor Antagonists to Low-Dose Inhaled Corticosteroids in the Elderly with Mild Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2642-2652.e3.	2.0	7

#	Article	IF	Citations
37	Cost-effectiveness of Tolvaptan for Euvolemic or Hypervolemic Hyponatremia. Clinical Therapeutics, 2014, 36, 1183-1194.	1.1	6
38	Comparison of Effectiveness Between Delamanid and Bedaquiline Among Patients with Multidrug-Resistant Tuberculosis: A Markov Model Simulation Study. Clinical Drug Investigation, 2016, 36, 957-968.	1.1	6
39	Current status of pharmacovigilance regulatory structures, processes, and outcomes in the Asiaâ€Pacific region: Survey results from 15 countries. Pharmacoepidemiology and Drug Safety, 2019, 28, 362-369.	0.9	6
40	Does Early Retrograde Intrarenal Surgery Improve the Cost-Effectiveness of Renal Stone Management?. Yonsei Medical Journal, 2020, 61, 515.	0.9	6
41	Lifetime effectiveness of mifamurtide addition to chemotherapy in nonmetastatic and metastatic osteosarcoma: a Markov process model analysis. Tumor Biology, 2015, 36, 6773-6779.	0.8	5
42	Patient and provider characteristics related with prescribing of <scp>ADHD</scp> medication: Nationwide health insurance claims database study in Korea. Asia-Pacific Psychiatry, 2018, 10, e12289.	1.2	5
43	Protonâ€pump inhibitors and the risk of <i>Clostridium difficile</i>â€"associated diarrhea in highâ€risk antibiotics users: A populationâ€based caseâ€crossover study. Pharmacoepidemiology and Drug Safety, 2019, 28, 479-488.	0.9	5
44	Real-world data analysis of the clinical and economic burden and risk factors in patients with major depressive disorder with an inadequate response to initial antidepressants. Journal of Medical Economics, 2021, 24, 589-597.	1.0	5
45	A comparison of discontinuation rates of tofacitinib and biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: a systematic review and Bayesian network meta-analysis. Clinical and Experimental Rheumatology, 2017, 35, 689-699.	0.4	5
46	Haematological cancer versus solid tumour end-of-life care: a longitudinal data analysis. BMJ Supportive and Palliative Care, 2020, , bmjspcare-2020-002453.	0.8	4
47	Cost-Effectiveness of Adjuvant Immunotherapy With Cytokine-Induced Killer Cell for Hepatocellular Carcinoma Based on a Randomized Controlled Trial and Real-World Data. Frontiers in Oncology, 2021, 11, 728740.	1.3	4
48	A Systematic Review of Economic Evaluations of Active Tuberculosis Treatments. Frontiers in Pharmacology, 2021, 12, 736986.	1.6	4
49	Cost implications of adverse drug event-related emergency department visits â€" a multicenter study in South Korea. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 139-146.	0.7	3
50	Therapeutic efficacy of new botulinum toxin identified in CCUG 7968 strain. Applied Microbiology and Biotechnology, 2021, 105, 8727-8737.	1.7	3
51	Adherence is an optimal factor for maximizing the effective and safe use of oral anticoagulants in patients with atrial fibrillation. Scientific Reports, 2022, 12, 3413.	1.6	3
52	Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis. Orphanet Journal of Rare Diseases, 2022, 17, .	1.2	3
53	Projection of future pharmacy service fees using the dispensing claims in hospital and clinic outpatient pharmacies: national health insurance database between 2006 and 2012. BMC Health Services Research, 2018, 18, 327.	0.9	2
54	Regulatory effect of decreasing therapeutic duplication of respiratory drugs using a prescription database between 2012 and 2015. Regulatory Toxicology and Pharmacology, 2019, 103, 218-228.	1.3	2

#	Article	IF	Citations
55	Prescribing Pattern and Safety Analysis of Nonsteroidal Anti-inflammatory Drug and Gastro-Protective Agent following Reimbursement Guidelines Relaxation. Korean Journal of Clinical Pharmacy, 2017, 27, 250-257.	0.0	2
56	Value-Based Pricing and Budget Impact Analysis for Multi-Indication Drugs: A Case Study of Immunotherapies. International Journal of Environmental Research and Public Health, 2022, 19, 4105.	1.2	2
57	Healthcare resource utilization and medical costs in patients with terminal cancer during best supportive care. PLoS ONE, 2022, 17, e0269565.	1.1	2
58	A benefit–risk assessment model for statins using multicriteria decision analysis based on a discrete choice experiment in Korean patients. Therapeutics and Clinical Risk Management, 2016, 12, 965.	0.9	1
59	Incremental impact of body mass status with modifiable unhealthy lifestyle behaviors on pharmaceutical expenditure. Research in Social and Administrative Pharmacy, 2016, 12, 990-1003.	1.5	1
60	Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea. Value in Health Regional Issues, 2017, 12, 7-19.	0.5	1
61	Risk of neuropsychiatric adverse events associated with the use of oseltamivir: a nationwide population-based case-crossover studyâ€"authorsâ€™ response. Journal of Antimicrobial Chemotherapy, 2019, 74, 1764-1765.	1.3	1
62	Development and Validation of a Trigger Tool for Identifying Drug-Related Emergency Department Visits. International Journal of Environmental Research and Public Health, 2021, 18, 8572.	1.2	1
63	Importance of a usual source of care in choosing low-priced generic drugs: a cross-sectional study. Family Practice, 2022, , .	0.8	1
64	Estimation of Health Utilities Based on the Response to Treatment in Atopic Dermatitis: a Population-based Study. Clinical Therapeutics, 2019, 41, 700-713.	1.1	0
65	FRI0374â€¦THE RISK OF INFECTION BY TUMOR NECROSIS FACTOR INHIBITORS AND ITS ASSOCIATED FACTORS IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULT FROM KOREAN NATIONAL HEALTH INSURANCE DATA. , 2019, , .		0
66	Analysis of Medical Use and Treatment Costs of Hepatocellular Carcinoma Patients Using National Patient Sample Data. Korean Journal of Clinical Pharmacy, 2021, 31, 153-159.	0.0	0
67	Comparative Analysis of Ethical-the-counter Drugs and Over-the-counter Drugs for the Adverse Events from the Community Pharmacy. Korean Journal of Clinical Pharmacy, 2018, 28, 230-237.	0.0	0
68	Development of Agenda for Pharmaceutical Care Service Research and Development using the Analytical Hierarchy Process. Korean Journal of Clinical Pharmacy, 2019, 29, 45-55.	0.0	0